Related Experiment Video
Updated: May 28, 2025

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
Sebaceous Carcinoma as a Presentation of Muir-Torre Syndrome
Emily Saurborn1, Bukola Adeshina1, Isabella G Stuart1
1Department of Dermatology, Marshall University Joan C. Edwards School of Medicine, Huntington, USA.
Muir-Torre syndrome, a rare cancer predisposition, can manifest as sebaceous adenocarcinoma. This case highlights the importance of immunohistochemistry for MSH2 and MLH1 loss in diagnosis.
Area of Science:
- Oncology
- Genetics
- Dermatology
Background:
- Muir-Torre syndrome (MTS) is a rare autosomal dominant condition within the Lynch syndrome spectrum.
- Sebaceous adenomas and various visceral malignancies characterize MTS.
- The Mayo score aids in identifying individuals at risk for MTS.
Observation:
- A case presenting a firm, red-yellow papule on the upper extremity.
- Biopsy revealed the lesion to be a sebaceous adenocarcinoma.
Findings:
- Immunohistochemistry demonstrated a loss of MSH2 and MLH1 expression.
- This finding is indicative of DNA mismatch repair deficiency, a hallmark of Lynch syndrome.
Implications:
- This case underscores the significance of recognizing sebaceous neoplasms in the context of potential Lynch syndrome.
- Early diagnosis and genetic counseling are crucial for affected individuals and their families.
- Understanding the molecular basis (MSH2/MLH1 loss) aids in risk stratification and management of associated cancers.
More Related Videos
06:15Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
04:12Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
Published on: December 19, 2019
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...